(Q46810855)

25 December 2017

meta-analysis

0 references

title

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis (English)

1 reference

25 December 2017

main subject

meta-analysis

0 references

author name string

Cholesterol Treatment Trialists' (CTT) Collaborators

1

1 reference

25 December 2017

P M Kearney

2

1 reference

25 December 2017

L Blackwell

3

1 reference

25 December 2017

R Collins

4

1 reference

25 December 2017

A Keech

5

1 reference

25 December 2017

J Simes

6

1 reference

25 December 2017

R Peto

7

1 reference

25 December 2017

J Armitage

8

1 reference

25 December 2017

C Baigent

9

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

25 December 2017

published in

The Lancet

1 reference

25 December 2017

volume

371

1 reference

25 December 2017

page(s)

117-125

1 reference

25 December 2017

issue

9607

1 reference

25 December 2017

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Serum Lipids and Lipoproteins in Insulin-treated Diabetes: Demonstration of Increased High Density Lipoprotein Concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Controlling lipid levels in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Report of the Conference on Low Blood Cholesterol: Mortality Associations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Are lipid-lowering guidelines evidence-based?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960104-X

7 January 2021

10.1016/S0140-6736(08)60104-X

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

18191683

1 reference

25 December 2017